AbCellera - FY2026 Q3 Earnings $ABCL $12.40 [-0.50% AH] ✅ Revenue: $10.6M (Est: $5.4M) [+19% YoY] ✅ EPS: -$0.13 (Est: -$0.18) [vs -$0.19 YoY] Segment Revenue: - Research fees: $10.5M [+20% YoY] - Licensing and royalty: $0.1M [-35% YoY] Additional Metrics: - Revenue up 163% QoQ from $4.1M - R&D expenses: $43.5M vs $55.0M YoY - SG&A expenses: $13.6M vs $25.0M YoY - Operating loss: $53.3M vs $76.3M YoY - Net loss: $40.8M vs $57.1M YoY - Cash and marketable securities: over $790M - Total available liquidity: over $890M, includes over $100M of non-dilutive government funding - Closed a $200M offering of common shares and pre-funded warrants in the quarter - Partner-led programs with an AbCellera downstream stake: 34 (down from 44 at Dec 31, 2025) Pipeline Update: - Positive top-line Phase 2 data for ABCL635 in hot flashes (moderate and severe VMS), late-stage development planned to start in 2027 - Phase 1 data for ABCL575 (OX40 ligand, atopic dermatitis) met all endpoints. No plan to develop it past Phase 1 - Three new programs advanced into IND-enabling work: ABCL992, ABCL385 and ABCL646